Regentis Biomaterials Ltd. closed its IPO, raising $10 million to advance its tissue repair solutions, particularly GelrinC.
Quiver AI Summary
Regentis Biomaterials Ltd. announced the successful closing of its initial public offering, selling 1.25 million ordinary shares at $8.00 per share, yielding gross proceeds of $10 million. The shares began trading on the NYSE American under the ticker "RGNT" on December 4, 2025, with underwriters given an option to purchase an additional 187,500 shares. The funds raised will primarily support the development of GerlinC, a hydrogel-based therapeutic for cartilage injuries, as well as repay debt and cover deferred compensation. Regentis is focused on regenerative medicine, specifically orthopedic treatments, and aims to commercialize its products in Europe while pursuing FDA approval in the United States. The offering was conducted under a finalized prospectus filed with the SEC.
Potential Positives
- The initial public offering (IPO) raised $10,000,000 in gross proceeds, providing substantial funding for the company's development activities and corporate purposes.
- Regentis Biomaterials' shares are now publicly traded on the NYSE American under the symbol "RGNT," which increases visibility and accessibility for investors.
- The company plans to use a portion of the proceeds to complete its pivotal clinical trial and prepare for PMA submission, indicating progress toward regulatory approval for its lead product, GelrinC.
Potential Negatives
- The closing of the initial public offering at a price of $8.00 per share may indicate a need for capital, suggesting potential financial instability or challenges in achieving profitability.
- The necessity to use the net proceeds for debt repayment and deferred compensation payments raises concerns about the company's current financial obligations and operational sustainability.
- The reliance on forward-looking statements highlights significant risks and uncertainties in the company’s future prospects, which may deter potential investors.
FAQ
What is Regentis Biomaterials Ltd. known for?
Regentis Biomaterials Ltd. specializes in regenerative medicine, focusing on innovative tissue repair solutions to enhance patient health and quality of life.
When did Regentis go public?
Regentis closed its initial public offering on December 5, 2025, with shares beginning to trade on December 4, 2025.
How much did Regentis raise in its IPO?
The company raised approximately $10,000,000 through the offering of 1,250,000 ordinary shares at $8.00 each.
What are the plans for the IPO proceeds?
Regentis plans to use the net proceeds primarily for development activities and corporate purposes, including debt repayment.
What is GelrinC by Regentis?
GelrinC is a cell-free hydrogel implant developed for treating knee cartilage injuries, approved in Europe with a CE mark.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments, if any.
The Ordinary Shares began trading on the NYSE American LLC on December 4, 2025, under the symbol “RGNT”.
The Company intends to use the net proceeds from the Offering primarily for development activities, including the completion of its pivotal trial, and preparation of the PMA submission for GerlinC, and also for corporate purposes including the repayment of certain debt and deferred compensation payments.
ThinkEquity acted as sole book-running manager for the Offering.
A Registration Statement on Form F-1 (File No. 333-285692) and amendments thereto relating to the Ordinary Shares sold in the Offering was filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective, as amended, on November 12, 2025. The Offering was made only by means of a prospectus. The final prospectus was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov . Copies of the final prospectus may also be obtained from ThinkEquity, 17 State Street, 41 st Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients. The Company’s current efforts are focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. GelrinC is Regentis’ cartilage injury therapeutic based on a unique hydrogel, erodible and resorbable, matrix of polyethylene glycol. The Company’s lead product candidate, GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into a temporary implant in the knee for the treatment of painful injuries to articular knee cartilage. GelrinC was approved as a device with a Conformité Européene mark in Europe, (CE mark number 3900600CE02). The Company plans to start commercialization efforts in Europe to bring its product to market, while being focused in parallel on completing its pivotal study for obtaining United States Food and Drug Administration approval. For more information, please visit https://www.regentis.co.il/
Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include the expected use of proceeds. Forward-looking statements are based on Regentis’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.
For Investor Relations Inquiries
Arie Gordashnikov
[email protected]
+972-3-6116629
